Barinthus Biotherapeutics (BRNS) Interest & Investment Income (2021 - 2026)

Barinthus Biotherapeutics (BRNS) has 6 years of Interest & Investment Income data on file, last reported at $350000.0 in Q1 2026.

• Quarterly Interest & Investment Income fell 37.05% year-over-year to $350000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (down 28.79% YoY) and the FY2025 annual result came in at $2.0 million, down 26.92% from the prior year.
• Interest & Investment Income declined to $350000.0 in Q1 2026, from $406000.0 in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $1.6 million in Q1 2023 to a low of $83000.0 in Q1 2022.
• A 5-year average of $645000.0 and a median of $571000.0 in 2023 frame the typical range for Interest & Investment Income.
• Annual changes were most pronounced in 2022 — Interest & Investment Income soared 4050.0% — and 2023, when it tumbled 80.86%.
• Tracing BRNS's Interest & Investment Income over 5 years: stood at $1.3 million in 2022, then tumbled by 56.97% to $571000.0 in 2023, then advanced by 11.56% to $637000.0 in 2024, then plunged by 36.26% to $406000.0 in 2025, then dropped by 13.79% to $350000.0 in 2026.
• The last three Interest & Investment Income figures came in at $350000.0 (Q1 2026), $406000.0 (Q4 2025), and $472000.0 (Q3 2025), per Business Quant data.